Tango Therapeutics enters $100M ATM offering with Leerink, terminates Jefferies ATM program

Tango Therapeutics, Inc.

New $100M at-the-market common stock sales agreement with Leerink Partners as agent, dated Nov 21, 2025.
Agent commission of up to 3.0% of gross sales price per share sold under the agreement.
Prior $100M Jefferies ATM program terminated effective Nov 21, 2025, with no penalties.
Shares to be sold via at-the-market or negotiated transactions at company's discretion.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Tango Therapeutics, Inc. terminated Open Market Sales Agreement SM (Jefferies Sales Agreement) with Jefferies LLC valued at termination of the 2022 ATM Program under which the Company could sell up to $100,000,000 of shares (effective 2025-11-21).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Value: termination of the 2022 ATM Program under which the Company could sell up to $100,000,000 of shares
Effective: 2025-11-21

Exact text from the filing

On November 18, 2025, the Company delivered written notice to Jefferies to terminate the Jefferies Sales Agreement, effective as of November 21, 2025, pursuant to Section 7(b)(i) thereof.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Tango Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $100,000,000 of shares of common stock (effective 2025-11-21).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $100,000,000 of shares of common stock
Effective: 2025-11-21

Exact text from the filing

On November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as sales agent (the “ATM Offering”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-290679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.